GSK’s SAM technology could revolutionise vaccines

October 30, 2019 Gubba Pharma In E News

At GSK, we work on vaccines aiming to help combat devastating infectious diseases like malaria, tuberculosis, HSV, RSV and COPD. Jeff Ulmer, Head Preclinical R&D US at GSK Vaccines explains how synthetic Self-Amplifying mRNA (SAM) and ground-breaking partnerships may help us fight more conditions faster and more efficiently than ever before.
Disrupting the field of vaccinology
Traditionally, scientific breakthroughs that change the way we understand and treat diseases often happen only once in a lifetime, sometimes even less. In my 40 years of working in scientific research I have seen great advances in the vaccine research and development, but I’ve never felt as close to a revolutionary breakthrough as I have in our current work in vaccines.
Today, our new technological capabilities allow us to intervene in biological interactions between our body and pathogens, which not only creates the potential for significant benefits for patients, it opens opportunities in many new disease areas, optimises the use of production facilities, and could help us make potent vaccines in a fraction of the typical development timeframes.

Source : gsk

Gubba Group

About the author

Gubba Group: